Another phase I clinical trial, studying the effects of investigational drug JNJ-40346527, a selective inhibitor of CSF-1R, on patients with high-risk PC that are resectable and showing no signs of local and distant metastasis, is currently active (NCT03177460). This evidence concerns the gene CSF1R and pachyonychia congenita.